Rapid response to dupilumab treatment in children with moderate-to-severe atopic dermatitis: A case series

Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease characterized by itch and clinical heterogeneity regarding the age of onset, morphology, distribution, and severity of lesions. Severe AD has a significant impact on the quality of life of affected children and their caregivers. Children with moderate-severe AD inadequately controlled with topical therapy have limited treatment options, such as systemic corticosteroids or phototherapy, often prescribed as off-label treatments, often with unfavorable benefit-to-risk ratio adverse events. Dupilumab is a fully human monoclonal antibody with proven effectiveness and a relatively safe adverse effect profile in patients with type 2 inflammatory diseases, including AD. We report three pediatric cases of severe AD successfully treated with dupilumab.

Automated summary

Atopic dermatitis (AD), a chronic and inflammatory skin disease, can have a significant impact on the quality of life for children and their caregivers. Severe cases of AD that are not effectively controlled with topical therapy often require systemic corticosteroids or phototherapy, but these treatments can have unfavorable adverse effects. Dupilumab, a fully human monoclonal antibody, has shown effectiveness in treating type 2 inflammatory diseases, including AD. This study reports successful treatment of severe AD in three pediatric cases using dupilumab.